Lagarde Reiterates ECB Is Well Placed to Navigate Uncertainty
By and Alexander Weber
Save
The European Central Bank is well placed to tackle 'exceptionally high' economic and political uncertainty, President Christine Lagarde said.
Addressing European lawmakers in Brussels, Lagarde said inflation is set to stabilize around the 2% goal and risks to economic growth remain tilted to the downside.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
an hour ago
- Fast Company
Hims & Hers stock plummets after Novo Nordisk ends partnership over 'knock-off' Wegovy
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health, Inc. (NYSE: HIMS), citing concerns over Hims & Hers' 'knock-off' weight loss drugs. Now, Hims & Hers' shares are plummeting as investors react to the news. It's the latest update in a somewhat volatile year for Hims & Hers. Just this April, the company's stock spiked after it initially announced a collaboration with Novo Nordisk that allowed Hims & Hers to sell Novo Nordisk's FDA-approved weight loss drug, Wegovy, through its platform. But less than two months later, that partnership is fracturing after Novo Nordisk's claim that Hims & Hers engaged in 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' At the time of this writing, HIMS stock is down 32.6% since market open. Here's what to know about the break-up: The shortage that fueled knock-off Wegovy Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand name drugs using their active ingredient, semaglutide, and sell them at a lower cost. Hims & Hers was one company that took part in selling a compounded—and non-FDA-approved—version of Wegovy. Then, this February, the FDA announced that Ozempic and Wegovy were no longer categorized under a shortage. With the brand name drugs fully back on the market, the FDA gave compounders 60 to 90 days to stop making copies of the patented drugs. At the time, Hims & Hers stated in a regulatory filing that, while it saw pathways to continue offering access to certain compounded GLP-1s after the shortage, it could not 'guarantee that we will be able to continue offering these products in the same manner, to the same extent, or at all.' However, an analyst told Reuters that Hims & Hers appeared poised to continue selling compounded semaglutide using 'personalized doses' after the shortage officially ended. Why is Novo Nordisk cutting ties now? In the wake of the FDA's shortage notice, Hims & Hers announced in April that it was entering a 'long-term collaboration' with Novo Nordisk to offer Wegovy directly to its consumers. Now, though, Novo Nordisk is breaking off the commitment over claims that Hims & Hers has not acted fast enough to stop selling its compounded GLP-1. Other telehealth companies, like Ro and Noom, have similarly faced criticism for continuing to sell their own compounded GLP-1 despite agreements with Eli Lilly, the maker of Zepbound. In an email to Fast Company, a Novo Nordisk spokesperson explained that 'semaglutide compounding is permitted under US compounding laws only in rare instances,' adding that other companies it's working with have 'demonstrated a good faith effort to transition patients to authentic, FDA-approved Wegovy.' However, the spokesperson continued, 'after over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that puts patient safety at risk. This is unacceptable and that is why we have decided to end the collaboration.' That personalization, involves offering the same drug; however, at different doses. In a press release published this morning, Novo Nordisk also noted that it is 'deeply concerned' about knock-off drugs 'made with foreign illicit active pharmaceutical ingredients.' 'Based on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China,' the release reads. 'According to a report from the Brookings Institute, FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers to make semaglutide, nor has FDA ever reviewed or authorized the quality of the 'semaglutide' they produce.' Hims & Hers did not immediately respond to Fast Company 's request for comment on Novo Nordisk's claims. On X, Novo Nordisk CEO Andrew Dudam said 'Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice.' He went on to say 'We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.'
Hamilton Spectator
an hour ago
- Hamilton Spectator
Canada signs new security and defence partnership with Europe
BRUSSELS - Canada and the European Union opened a new era of transatlantic co-operation Monday with the official signing of a security and defence partnership at a joint summit in Brussels. The agreement commits Canada and Europe to collaboration on defence and is a step toward Canada participating in the continent's massive new defence procurement program, known as ReArm Europe. Prime Minister Mark Carney, who travelled to Brussels for the Canada-EU Summit, is pursuing more options for defence procurement as Canada seeks to reduce its reliance on the United States. Carney met with European Council President António Costa and European Commission President Ursula von der Leyen at the summit, before the final deal was signed. Costa said Canada and the EU are 'looking at the world through the same lens' and this meeting has taken the partnership to a new level. Von der Leyen told Carney he was 'here among friends.' She said Canada and the EU are two strong democracies bound by historic ties and connected by a 'dynamic, fair and open' trade partnership. She said the EU wants not just to reaffirm the friendship and partnership with Canada but also to reshape it. She said the agreement is the 'most comprehensive' ever completed. 'We know we can count on you and you can count on us,' she said. Carney said the leaders are putting into practice some of what they discussed at the G7 and have been working on for years. Carney said the deal is crucial for Canada and 'shows a way forward.' Under the terms of the agreement, Canada and the EU will hold an annual 'security and defence dialogue' involving top officials. The agreement also commits both partners to expanding co-operation in support of Ukraine, improving Canadian military mobility in Europe and enhancing maritime co-operation in regions of 'mutual interest' like the Indo-Pacific. Canada will need to sign a second agreement with the European Commission before it can take part in the 150-billion-euro ReArm Europe initiative. The security and defence agreement also pledges further collaboration on emerging issues in cybersecurity, foreign interference, disinformation and outer space policy. Carney also met with Belgian Prime Minister Bart De Wever ahead of the Canada-EU Summit. De Wever said that Canada's partnership with the EU is vital now because 'we've woken up in a world that doesn't look that friendly anymore.' A government official briefing reporters on the trip said the partnership is expected to make procurement easier and more affordable, while also allowing Canada to diversify its sources of equipment. On Tuesday, Carney travels to The Hague for the NATO summit, where member nations will decide whether to fully endorse a substantial increase in the defence spending target, from two per cent of GDP to five per cent. Carney said earlier this month Canada would increase its defence spending this year to meet the two per cent target for the first time since it was established in 2014. This report was first published by The Canadian Press on Jun 23, 2025.
Washington Post
an hour ago
- Washington Post
NATO is worth paying for. Trump is right that Europe needs to do more.
President Donald Trump will attend the first NATO summit of his second term Tuesday, at a time when the alliance's 21st-century relevance has never been clearer — but when its sustainability is also in question, with a NATO-skeptical American president back in the Oval Office. Given these realities, Europe needs to show it will contribute its share to ensure the alliance is stable and strong.
